The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

Bavarian's JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and ...

The first 300 doses were administered on Tuesday near the border with the Democratic Republic of Congo, a spokesperson for ...

Bavarian Nordic’s MVA-BN vaccine is called Imvanex in Europe but is known as Jynneos in countries such as the US and ...

Gavi, the Vaccine Alliance, will purchase 500,000 doses of MVA-BN, the Bavarian Nordic Mpox vaccine, as part of an ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

Health Minister of Indian state of Kerala, Veena George, said on Thursday that genome sequencing will be conducted to ...

Rwanda has launched the first mpox vaccination campaign in Africa, marking a significant step in the continent's fight ...

Rwanda has started a vaccination campaign against mpox with 1,000 doses of the vaccine it obtained from Nigeria under an ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.